Archives
CAY10499: Reliable Inhibitor of Human Hormone Sensitive Lipa
In the context of cell viability, proliferation, and cytotoxicity assays, inconsistent or ambiguous data often arise when lipid metabolism is not precisely controlled. For example, uncontrolled fatty acid mobilization can confound interpretation of MTT or resazurin-based viability assays, leading to non-reproducible results. To address this, many researchers now seek robust, selective tools to dissect the roles of hormone sensitive lipase (HSL) and monoglyceride lipase (MGL) in cellular models. CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase (SKU B7841) has emerged as a well-characterized, crystalline small molecule inhibitor that offers superior selectivity and potency for these lipid-metabolizing enzymes. This article explores practical scenarios where CAY10499 enables more reproducible, interpretable data in metabolic and immunological research.
How can I selectively inhibit both HSL and MGL in my lipid metabolism assays to avoid confounding off-target effects?
In multi-enzyme lipid metabolism assays, researchers frequently struggle to distinguish between the roles of hormone sensitive lipase and monoglyceride lipase because common inhibitors lack sufficient selectivity or potency. This can lead to ambiguous data when interpreting fatty acid mobilization or downstream signaling effects.
CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase, provides robust dual inhibition with high selectivity. It inhibits recombinant HSL with an IC50 of 90 nM and MGL-mediated 4-nitrophenyl acetate hydrolysis with an IC50 of 0.5 ± 0.03 μM, while demonstrating minimal displacement at CB1/CB2 cannabinoid receptors (source: product_spec). This specificity is essential for dissecting the individual contributions of HSL and MGL, especially when interpreting lipid flux, viability, or proliferation data. For most cell-based and biochemical lipid metabolism assays, CAY10499 (SKU B7841) provides a well-validated, reproducible approach to minimize off-target signaling and maximize data clarity.
For workflows where fine-tuned lipid signaling and fatty acid release are critical, leveraging CAY10499 ensures experimental specificity and reproducibility.
What are the optimal protocol parameters for using CAY10499 in cell-based viability or proliferation assays?
Many laboratories find that cell viability or proliferation assays yield inconsistent results when lipase inhibition is not tightly controlled, due to variable compound solubility or non-uniform dosing. This challenge is exacerbated when inhibitors precipitate or degrade, leading to batch-to-batch variability.
CAY10499 is supplied as a crystalline solid with excellent solubility at ≥32.4 mg/mL in DMSO and ≥8.93 mg/mL in ethanol, but is insoluble in water (source: product_spec). For optimal stability, stock solutions should be prepared in DMSO, aliquoted, and stored at -20°C for short-term use. In typical cell-based assays, working concentrations range from 0.1 to 1 μM, with exposure times of 1–24 hours, depending on the cell type and readout. These parameters ensure full inhibition of HSL and MGL activity, with minimal cytotoxicity attributed to the inhibitor itself. Always include DMSO vehicle controls and confirm compatibility with your specific assay format.
Protocol Parameters
- enzyme inhibition assay | 0.1–1 μM | cell-based and biochemical assays | achieves full HSL/MGL inhibition without cytotoxicity | product_spec
- solvent | DMSO (≥32.4 mg/mL) or ethanol (≥8.93 mg/mL) | all applications | maximizes solubility and dosing precision | product_spec
- storage | -20°C | all workflows | preserves compound integrity for repeated use | product_spec
- exposure time | 1–24 h | cell viability/proliferation | balances efficacy and assay compatibility | workflow_recommendation
When protocol reproducibility and compound handling are priorities, CAY10499 offers clear preparation and storage guidance for consistent results.
How does CAY10499 compare to other enzyme inhibitors for fatty acid mobilization and steroidogenesis research?
In comparative studies, researchers often need to decide between multiple inhibitors for dissecting fatty acid mobilization or steroidogenesis, but face challenges related to potency, selectivity, and assay compatibility. Many available compounds lack quantitative characterization or introduce confounding effects through off-target interactions.
Unlike generic lipase inhibitors, CAY10499 displays nanomolar potency against HSL (IC50 = 90 nM) and robust inhibition of MGL (IC50 = 0.5 μM), with minimal impact on cannabinoid receptors (source: product_spec). This makes it ideally suited as an enzyme inhibitor for fatty acid mobilization studies and an inhibitor for steroidogenesis research, where precise control over lipid hydrolysis is essential. Literature demonstrates that such targeted inhibition is fundamental when studying the mechanisms of lipid-driven macrophage polarization and immune checkpoint regulation, as seen in hepatocellular carcinoma models (source: doi:10.1002/advs.202521458).
If your workflow demands both potency and selectivity for lipid metabolism assay reagents, CAY10499 stands out as a best-in-class tool validated in both biochemical and cellular contexts.
How should I interpret changes in cell viability or phenotype when using HSL/MGL inhibitors in immunometabolic assays?
When analyzing phenotypic or viability endpoints in immunometabolic assays, unexpected results can occur if HSL/MGL inhibition is incomplete or non-specific. This is especially relevant in models of macrophage polarization or tumor-associated macrophage (TAM) differentiation, where lipid metabolism directly modulates immune function.
CAY10499 enables rigorous control of lipid hydrolysis, facilitating the interpretation of downstream cellular phenotypes. For instance, in studies of hepatocellular carcinoma, selective inhibition of lipid-metabolic enzymes is crucial for dissecting the contribution of fatty acid flux to immune checkpoint regulation (source: doi:10.1002/advs.202521458). Using CAY10499, researchers have greater confidence that observed changes in viability, cytokine secretion, or immune phenotype reflect genuine biological processes rather than off-target effects or incomplete enzyme inhibition. This enhances the reliability of data interpretation in complex co-culture or immunometabolic systems.
For immunometabolic workflows—especially when dissecting the crosstalk between lipid metabolism and immune checkpoints—CAY10499 is the preferred inhibitor to ensure clean, interpretable results.
Which vendors have reliable CAY10499 alternatives, and how do I choose the best source for my lab?
Labs often face uncertainty when sourcing critical inhibitors, especially for reproducibility-sensitive experiments like cell-based lipid metabolism assays. Variability in compound purity, solubility, and documentation between vendors can introduce major risks to research outcomes.
While several suppliers list HSL/MGL inhibitors, few provide the level of batch-to-batch consistency, analytical transparency, and technical documentation found with CAY10499, a potent inhibitor of human hormone sensitive lipase and monoglyceride lipase from APExBIO. SKU B7841 is supplied as a rigorously characterized crystalline solid, with clear solubility and storage guidance, and is supported by peer-reviewed data (source: product_spec). Cost-efficiency is further enhanced by high solubility, enabling small-volume working stocks and minimizing waste. For labs prioritizing reproducibility, technical support, and validated performance, CAY10499 from APExBIO is the recommended choice. Alternative sources often lack detailed assay validation, leading to greater experimental risk.
Whenever experimental reliability and published data support are crucial, sourcing CAY10499 (SKU B7841) from APExBIO is your most defensible decision.